Toll-like receptor 4 and hepatic fibrogenesis

Seminars in Liver Disease

Volumn 30, Issue 3, 2010, Pages 232-244

  Pradere, Jean Philippe ^a   Troeger, Juliane S ^a   Dapito, Dianne H ^a   Mencin, Ali A ^a   Schwabe, Robert F ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

fibrogenesis; hepatic injury; LPS; TLR4

Indexed keywords

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; ANTIBIOTIC AGENT; BACITRACIN; CD14 ANTIGEN; ERITORAN; GADOLINIUM CHLORIDE; HIGH MOBILITY GROUP B1 PROTEIN; HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; NEOMYCIN; NORFLOXACIN; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ALCOHOL LIVER DISEASE; BACTERIAL PERITONITIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DRUG BINDING; FIBROGENESIS; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; INTESTINE FLORA; KUPFFER CELL; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; LIGAND BINDING; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOCOCCUS THERMOPHILUS;

ANIMALS; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELLS; HEPATITIS; HUMANS; INFLAMMATION MEDIATORS; LIGANDS; LIVER; LIVER CIRRHOSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 77954961993     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0030-1255353     Document Type: Review

References (120)

1. Janeway C A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989 54 (Pt 1) 1-13
2. Lemaitre B, Nicolas E, Michaut L, Reichhart J M., Hoffmann J A. The dorsoventral regulatory gene cassette sptzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996 86 973-983
3. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998 282 2085-2088
4. O'Neill L A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008 226 10-18
5. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008 1143 1-20
6. Gay N J., Keith F J. Drosophila Toll and IL-1 receptor. Nature 1991 351 355-356
7. Freudenberg M A., Tchaptchet S, Keck S et al. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity. Immunobiology 2008 213 193-203
8. Kim H M., Park B S., Kim J I. et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007 130 906-917
9. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004 4 499-511
10. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006 124 783-801
11. Horng T, Barton G M., Flavell R A., Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002 420 329-333
12. Yamamoto M, Sato S, Hemmi H et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002 420 324-329
13. Yamamoto M, Sato S, Hemmi H et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003 4 1144-1150 (Pubitemid 37428043)
14. Pfeiffer R. Untersuchungen u?ber das Choleragift. Z Hygiene 1892 11 393-412
15. Alexander C, Rietschel E T. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001 7 167-202
16. Jiang Z, Georgel P, Du X et al. CD14 is required for MyD88-independent LPS signaling. Nat Immunol 2005 6 565-570
17. Huber M, Kalis C, Keck S et al. R-form LPS, the master key to the activation ofTLR4/MD-2-positive cells. Eur J Immunol 2006 36 701-711
18. Beutler B. Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease. Immunol Rev 2007 220 113-128
19. Lotze M T., Zeh H J., Rubartelli A et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007 220 60-81
20. Kono H, Rock K L. How dying cells alert the immune system to danger. Nat Rev Immunol 2008 8 279-289
21. Lee J Y., Zhao L, Youn H S. et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004 279 16971-16979
22. Shi H, Kokoeva M V., Inouye K, Tzameli I, Yin H, Flier J S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006 116 3015-3025
23. Tsan M F., Baochong Gao. Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J Endotoxin Res 2007 13 6-14
24. Tsung A, Sahai R, Tanaka H et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005 201 1135-1143
25. Seki E, De Minicis S, Osterreicher C H. et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007 13 1324-1332
26. Bianchi M E., Manfredi A A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007 220 35-46
27. Lotze M T., Tracey K J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005 5 331-342
28. Bonaldi T, Talamo F, Scaffidi P et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003 22 5551-5560
29. Scaffidi P, Misteli T, Bianchi M E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002 418 191-195
30. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007 81 49-58
31. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008 180 2531-2537
32. Tian J, Avalos A M., Mao S Y. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007 8 487-496
33. Youn J H., Oh Y J., Kim E S., Choi J E., Shin J S. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008 180 5067-5074
34. Jiang D, Liang J, Noble P W. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007 23 435-461
35. Jiang D, Liang J, Fan J et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005 11 1173-1179
36. Taylor K R., Trowbridge J M., Rudisill J A., Termeer C C., Simon J C., Gallo R L. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004 279 17079-17084
37. Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002 195 99-111
38. Nanji A A., Khettry U, Sadrzadeh S M. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994 205 243-247
39. Adachi Y, Moore L E., Bradford B U., Gao W, Thurman R G. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995 108 218-224
40. Adachi Y, Bradford B U., Gao W, Bojes H K., Thurman R G. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994 20 453-460
41. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003 37 343-350
42. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff S C., Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009 50 1094-1104
43. Rivera C A., Bradford B U., Hunt K J. et al. Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol 2001 281 G200-G207
44. Duffield J S., Forbes S J., Constandinou C M. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005 115 56-65
45. Su G L., Klein R D., Aminlari A et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 2000 31 932-936
46. Seki E, Tsutsui H, Nakano H et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 2001 166 2651-2657
47. Kopydlowski K M., Salkowski C A., Cody M J. et al. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 1999 163 1537-1544
48. Lichtman S N., Wang J, Lemasters J J. LPS receptor CD14 participates in release of TNF-alpha in RAW 264.7 and peritoneal cells but not in Kupffer cells. Am J Physiol 1998 275 (1 Pt 1) G39-G46
49. Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Bschenfelde K H., Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol 1995 22 226-229
50. Schuchmann M, Hermann F, Herkel J, van der Zee R, Galle P R., Lohse A W. HSP60 and CpG-DNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells. Immunol Lett 2004 93 199-204
51. Van Bossuyt H, De Zanger R B., Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts. J Hepatol 1988 7 325-337
52. Fox E S., Thomas P, Broitman S A. Clearance of gut-derived endotoxins by the liver. Release and modification of 3H, 14C-lipopolysaccharide by isolated rat Kupffer cells. Gastroenterology 1989 96 (2 Pt 1) 456-461
53. Mimura Y, Sakisaka S, Harada M, Sata M, Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology 1995 109 1969-1976
54. Shao B, Lu M, Katz S C. et al. A host lipase detoxifies bacterial lipopolysaccharides in the liver and spleen. J Biol Chem 2007 282 13726-13735
55. Matsumura T, Degawa T, Takii T et al. TRAF6-NF-kappaB pathway is essential for interleukin-1-induced TLR2 expression and its functional response to TLR2 ligand in murine hepatocytes. Immunology 2003 109 127-136
56. Matsumura T, Ito A, Takii T, Hayashi H, Onozaki K. Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes. J Interferon Cytokine Res 2000 20 915-921
57. Friedman S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008 88 125-172
58. Paik Y H., Schwabe R F., Bataller R, Russo M P., Jobin C, Brenner D A. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003 37 1043-1055
59. Kao Y H., Jawan B, Goto S et al. High-mobility group box 1 protein activates hepatic stellate cells in vitro. Transplant Proc 2008 40 2704-2705
60. Connolly M K., Bedrosian A S., Mallen-St Clair J et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009 119 3213-3225
61. Chen X M., O'Hara S P., Nelson J B. et al. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB. J Immunol 2005 175 7447-7456
62. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005 41 422-433
63. Wells C L., Maddaus M A., Reynolds C M., Jechorek R P., Simmons R L. Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect Immun 1987 55 2689-2694
64. Fukui H, Brauner B, Bode J C., Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991 12 162-169
65. Parlesak A, Schfer C, Schtz T, Bode J C., Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000 32 742-747
66. Mathurin P, Deng Q G., Keshavarzian A, Choudhary S, Holmes E W., Tsukamoto H. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology 2000 32 1008-1017
67. Lin R S., Lee F Y., Lee S D. et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995 22 165-172
68. Rivera C A., Bradford B U., Seabra V, Thurman R G. Role of endotoxin in the hypermetabolic state after acute ethanol exposure. Am J Physiol 1998 275 (6 Pt 1) G1252-G1258
69. Steffen E K., Berg R D., Deitch E A. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis 1988 157 1032-1038
70. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008 28 26-42
71. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 1991 24 219-239
72. Bataller R, Brenner D A. Liver fibrosis. J Clin Invest 2005 115 209-218
73. Nolan J P., Leibowitz A I. Endotoxin and the liver. III. Modification of acute carbon tetrachloride injury by polymyxin ban antiendotoxin. Gastroenterology 1978 75 445-449
74. Grinko I, Geerts A, Wisse E. Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia. J Hepatol 1995 23 449-458
75. Chan C C., Hwang S J., Lee F Y. et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 1997 32 942-946
76. Luckey T D., Reyniers J A., Gyorgy P, Forbes M. Germfree animals and liver necrosis. Ann N Y Acad Sci 1954 57 932-935
77. Rutenburg A M., Sonnenblick E, Koven I, Aprahamian H A., Reiner L, Fine J. The role of intestinal bacteria in the development of dietary cirrhosis in rats. J Exp Med 1957 106 1-14
78. Isayama F, Hines I N., Kremer M et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol 2006 290 G1318-G1328
79. Poelstra K, Popov Y, Sverdlov D Y., Sharma A, Schuppan D. Gut-derived bacterial products drive progression of liver fibrosis in mdr2/mice: Involvement of LPS and TLR4. Hepatology 2009 50 819A
80. Watanabe A, Hashmi A, Gomes D A. et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007 46 1509-1518
81. Gabele E, Muhlbauer M, Dorn C et al. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 2008 376 (2) 271-276
82. Seki E, De Minicis S, Gwak G Y. et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009 119 1858-1870
83. Huang H, Shiffman M L., Friedman S et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007 46 297-306
84. Li Y, Chang M, Abar O et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 2009 51 750-757
85. Von Hahn T, Halangk J, Witt H et al. Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease. Scand J Gastroenterol 2008 43 584-592
86. Guo J, Loke J, Zheng F et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009 49 960-968
87. Bjarnason I, Peters T J., Wise R J. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984 1 179-182
88. Draper L R., Gyure L A., Hall J G., Robertson D. Effect of alcohol on the integrity of the intestinal epithelium. Gut 1983 24 399-404
89. Uesugi T, Froh M, Arteel G E., Bradford B U., Thurman R G. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001 34 101-108 (Pubitemid 32591488)
90. Hansen J, Cherwitz D L., Allen J I. The role of tumor necrosis factor-alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats. Hepatology 1994 20 461-474
91. Hritz I, Mandrekar P, Velayudham A et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008 48 (4) 1224-1231
92. Kono H, Rusyn I, Yin M et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 2000 106 867-872
93. Yang S Q., Lin H Z., Lane M D., Clemens M, Diehl A M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997 94 2557-2562
94. Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005 29 (11 Suppl) 140S-145S
95. Rivera C A., Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007 47 571-579
96. Cani P D., Amar J, Iglesias M A. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007 56 1761-1772
97. Cani P D., Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008 57 1470-1481
98. Cope K, Risby T, Diehl A M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000 119 1340-1347
99. Nair S, Cope K, Risby T H., Diehl A M., Terence R H. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001 96 1200-1204
100. Adawi D, Kasravi F B., Molin G, Jeppsson B. Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat. Hepatology 1997 25 642-647 (Pubitemid 27106447)
101. Ewaschuk J, Endersby R, Thiel D et al. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007 46 841-850
102. Osman N, Adawi D, Ahrn S, Jeppsson B, Molin G. Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Dig Liver Dis 2007 39 849-856
103. Liu Q, Duan Z P., Ha D K., Bengmark S, Kurtovic J, Riordan S M. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004 39 1441-1449
104. Rayes N, Seehofer D, Hansen S et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002 74 123-127
105. Rayes N, Seehofer D, Theruvath T et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantationa randomized, double-blind trial. Am J Transplant 2005 5 125-130
106. Loguercio C, Federico A, Tuccillo C et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005 39 540-543
107. Velayudham A, Dolganiuc A, Ellis M et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009 49 989-997
108. Runyon B A., Borzio M, Young S, Squier S U., Guarner C, Runyon M A. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis. Hepatology 1995 21 1719-1724
109. Llovet J M., Bartol R, Planas R et al. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. Hepatology 1996 23 781-787
110. Bauer T M., Fernndez J, Navasa M, Vila J, Rods J. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol 2002 36 501-506
111. Fernndez J, Navasa M, Planas R et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007 133 818-824
112. Runyon B A. A pill a day can improve survival in patients with advanced cirrhosis. Gastroenterology 2007 133 1029-1031
113. Mullarkey M, Rose J R., Bristol J et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003 304 1093-1102
114. Rossignol D P., Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002 8 483-488
115. Fort M M., Mozaffarian A, Stver A G. et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005 174 6416-6423
116. Ii M, Matsunaga N, Hazeki K et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 2006 69 1288-1295
117. Kawamoto T, Ii M, Kitazaki T, Iizawa Y, Kimura H. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 2008 584 40-48
118. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 2007 571 231-239
119. Schnabl B, Brandl K, Fink M et al. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun 2008 375 210-214
120. Kanzler H, Barrat F J., Hessel E M., Coffman R L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007 13 552-559